GSK-2636771 Active Not Recruiting Phase 2 Trials for Ovarian Carcinoma / Recurrent Breast Carcinoma / Recurrent Head and Neck Carcinoma / Rectal Carcinoma / Recurrent Melanoma / Breast Carcinoma / Colon Carcinoma / Multiple Myeloma (MM) / Recurrent Ovarian Carcinoma / Hepatocellular Carcinoma / Recurrent Malignant Solid Neoplasm / Refractory Multiple Myeloma / Advanced Lymphomas / Recurrent Pancreatic Carcinoma / Recurrent Lung Carcinoma / Lung Carcinoma / Colorectal Carcinoma (CRC) / Bladder Carcinoma / Advanced Malignant Solid Tumor / Cervical Carcinoma / Recurrent Skin Carcinoma / Recurrent Rectal Carcinoma / Recurrent Lymphoma / Prostate Carcinoma / Lymphoma / Recurrent Gliomas / Pancreatic Carcinoma / Refractory Lymphomas / Recurrent Liver Carcinoma / Recurrent Prostate Carcinoma / Carcinoma of the Head and Neck / Recurrent Thyroid Gland Carcinoma / Hematopoietic and Lymphoid System Neoplasm / Refractory Malignant Solid Neoplasm / Uterine Corpus Cancer / Recurrent Cervical Carcinoma / Recurrent Colorectal Carcinoma / Endometrial Carcinoma / Malignant Uterine Neoplasm / Esophageal Carcinoma / Melanoma / Glioma / Recurrent Uterine Corpus Cancer / Recurrent Colon Carcinoma / Carcinoma of the Skin / Recurrent Esophageal Carcinoma / Renal Carcinoma / Thyroid Gland Carcinoma / Recurrent Gastric Carcinoma / recurrent multiple myeloma / Recurrent Bladder Carcinoma / Gastric Carcinoma Screening

IndicationsStatusPurposePhase
Active Not RecruitingScreening2
clinicaltrials.gov IdentifierTitleDrugs
NCT02465060Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)